Aldeyra Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
/ 
Frequently asked questions
To buy Aldeyra Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Aldeyra Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Aldeyra Therapeutics Inc. is ALDX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Aldeyra Therapeutics Inc. has its primary listing on NASDAQ (Small cap). You can trade Aldeyra Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Aldeyra Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Aldeyra Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Aldeyra Therapeutics Inc..